Catalent, Inc. (NYSE: CTLT), is a global leader in enabling pharma, biotech, and consumer
health partners to optimize product development, launch, and full life-cycle supply for patients
around the world. With broad and deep scale and expertise in development sciences, delivery
technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for
personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps
accelerate over 1,500 partner development programs and launch over 150 new products every year.
Its flexible manufacturing platforms at over 50 global sites supply nearly 70 billion doses of
nearly 8,000 products annually. Catalent’s expert workforce of approximately 17,000 includes
more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company
generated approximately $4.4 billion in revenue in its 2024 fiscal year. www.catalent.com.